The regulatory uncertainty around biosimilars in the United States is finally lifting, just months after the first biosimilar monoclonal antibody hit the US market.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
31 March 2017
The article has been updated to indicate that Sandoz ran a confirmatory study in chronic plaque psoriasis of its etanercept biosimilar versus active comparator, rather than versus placebo
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Bracing for the biosimilar wave. Nat Rev Drug Discov 16, 152–154 (2017). https://doi.org/10.1038/nrd.2017.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.36
This article is cited by
-
Rituximab for the treatment of multiple sclerosis: a review
Journal of Neurology (2022)
-
Erratum: Bracing for the biosimilar wave
Nature Reviews Drug Discovery (2017)
